NCT06563115View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 18, 2022

Primary Completion Date

April 23, 2024

Study Completion Date

June 23, 2024

Conditions
Insulin Resistance
Interventions
DRUG

(PEG)-BHD1028 Single Ascending Dose

4, 8, 16, 32, and 64 μg/Kg

DRUG

(PEG)-BHD1028 Multiple Ascending Dose

8, 16, and 32 μg/Kg

OTHER

Placebo

Diluent

Trial Locations (1)

66212

Altasciences Clinical, Overland Park

All Listed Sponsors
lead

EncuraGen, Inc

INDUSTRY